We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
- Authors
Perez, Edith A; Romond, Edward H; Suman, Vera J; Jeong, Jong-Hyeon; Davidson, Nancy E; Geyer, Charles E, Jr; Martino, Silvana; Mamounas, Eleftherios P; Kaufman, Peter A; Wolmark, Norman
- Abstract
Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North Central Cancer Treatment Group (NCCTG) N9831 Intergroup trial and National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial were reported in 2005. Long-term follow-up results on disease-free survival (DFS) and overall survival (OS) have been awaited.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 25, p3366
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.35.0868